Avidity of onconeural antibodies is of clinical relevance

Cancer Immunology, Immunotherapy

Volumn 62, Issue 8, 2013, Pages 1393-1396

  Totland, Cecilie ^a   Ying, Ming ^b   Haugen, Mette ^a   Mazengia, Kibret ^b   Storstein, Anette ^a   Aarseth, Jan ^a   Martinez, Aurora ^b   Vedeler, Christian ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Avidity; Immunoprecipitation; Onconeural antibody; Plasmon resonance

Indexed keywords

ANTIBODY; CRMP5 ANTIBODY; HU ANTIBODY; ONCONEURAL ANTIBODY; UNCLASSIFIED DRUG; YO ANTIBODY;

ARTICLE; ASTROCYTOMA; COLON CANCER; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOPRECIPITATION; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOPRECIPITATION; NERVE TISSUE PROTEINS; PARANEOPLASTIC SYNDROMES; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE;

EID: 84880925023     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1442-6     Document Type: Article

References (19)

1. Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543-1554
2. Storstein A, Vedeler CA (2007) Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem 44:143-185
3. Pittock SJ, Kryzer TJ, Lennon VA (2004) Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56:715-719
4. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135-1140
5. de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71:815-824
6. Totland C, Aarseth J, Vedeler C (2007) Hu and Yo antibodies have heterogeneous avidity. J Neuroimmunol 185:162-167
7. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B (2004) High avidity anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 63:1478-1482
8. Comin R, Yuki N, Lopez PH, Nores GA (2006) High affinity of anti-GM1 antibodies is associated with disease onset in experimental neuropathy. J Neurosci Res 84:1085-1090
9. Leite MI, Waters P, Vincent A (2010) Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 43:371-379
10. Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, Lohndal E, Aarseth J, Vedeler C (2011) Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol 232:166-1670
11. Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA (2004) Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22:795-800
12. Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 144:53-58
13. Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA (2008) CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother 57:227-232
14. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 58:1795-1800
15. Hedman K, Rousseau SA (1989) Measurement of avidity of specific IgG for verification of recent primary rubella. J Med Virol 27:288-292
16. Hutsell SQ, Kimple RJ, Siderovski DP, Willard FS, Kimple AJ (2010) High affinity immobilization of proteins using biotin- and GST-based coupling strategies. Methods Mol Biol 627:75-90
17. Jönsson U, Fägerstam L, Ivarsson B, Johnsson B, Karlsson R, Lundh K, Löfås S, Persson B, Roos H, Rönnberg I (1991) Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 11:620-627
18. McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA (2011) Purkinje cell cytoplasmic autoantibody type 1 accompaniments. Arch Neurol 68:1282-1289
19. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG (2010) Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 69:997-1007